Seeking Alpha

BioLineRx (BLRX) trades higher before the bell after saying it received regulatory approval to...

BioLineRx (BLRX) trades higher before the bell after saying it received regulatory approval to commence a Phase IIa trial for its BL-8040 Leukemia drug. The primary endpoints are safety and tolerability. BLRX lost over half its market cap in March after discontinuing a clinical trial for an antipsychotic. Shares +7% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|